Novakand Pharma AB (publ) (LARK) - Cash Flow Conversion Efficiency

Latest as of June 2026: 0.006x

Based on the latest financial reports, Novakand Pharma AB (publ) (LARK) has a cash flow conversion efficiency ratio of 0.006x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr352.00K ≈ $37.88K USD) by net assets (Skr56.71 Million ≈ $6.10 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Novakand Pharma AB (publ) worth for the company's overall valuation and market capitalisation.

Novakand Pharma AB (publ) - Cash Flow Conversion Efficiency Trend (2012–2025)

This chart illustrates how Novakand Pharma AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Novakand Pharma AB (publ) (LARK) stock price for real-time trading data and today's change.

Novakand Pharma AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Novakand Pharma AB (publ) ranked by their cash flow conversion efficiency. Review Novakand Pharma AB (publ) free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.

Company	Cash Flow Conversion Efficiency
Tourn International AB ST:TOURN	0.052x
Kontigo Care AB ST:KONT	0.046x
Manchester and London Investment Trust plc LSE:MNL	-0.006x
Polar Power Inc NASDAQ:POLA	0.023x
Bang Overseas Limited NSE:BANG	-0.049x
DomaCom Limited AU:DCL	0.000x
Chenghe Acquisition II Co. NYSE MKT:CHEB	-0.002x
Suvidhaa Infoserve Limited NSE:SUVIDHAA	-0.075x

Annual Cash Flow Conversion Efficiency for Novakand Pharma AB (publ) (2012–2025)

The table below shows the annual cash flow conversion efficiency of Novakand Pharma AB (publ) from 2012 to 2025. Also see LARK current and non-current assets for a full breakdown of the balance sheet.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr55.49 Million ≈ $5.97 Million	Skr-12.78 Million ≈ $-1.38 Million	-0.230x	+44.96%
2024-12-31	Skr71.58 Million ≈ $7.70 Million	Skr-29.95 Million ≈ $-3.22 Million	-0.418x	-59.46%
2023-12-31	Skr116.46 Million ≈ $12.53 Million	Skr-30.56 Million ≈ $-3.29 Million	-0.262x	-139.51%
2022-12-31	Skr152.12 Million ≈ $16.37 Million	Skr-16.67 Million ≈ $-1.79 Million	-0.110x	-178.41%
2021-12-31	Skr158.28 Million ≈ $17.03 Million	Skr22.11 Million ≈ $2.38 Million	0.140x	+126.03%
2020-12-31	Skr71.43 Million ≈ $7.69 Million	Skr-38.35 Million ≈ $-4.13 Million	-0.537x	+49.55%
2019-12-31	Skr20.30 Million ≈ $2.19 Million	Skr-21.60 Million ≈ $-2.33 Million	-1.064x	-9662.78%
2018-12-31	Skr20.46 Million ≈ $2.20 Million	Skr227.60K ≈ $24.49K	0.011x	+100.76%
2017-12-31	Skr6.51 Million ≈ $700.81K	Skr-9.53 Million ≈ $-1.03 Million	-1.463x	+32.24%
2016-12-31	Skr4.08 Million ≈ $439.02K	Skr-8.81 Million ≈ $-947.94K	-2.159x	-252.65%
2015-12-31	Skr10.27 Million ≈ $1.10 Million	Skr-6.29 Million ≈ $-676.42K	-0.612x	-458.89%
2014-12-31	Skr5.67 Million ≈ $609.68K	Skr-620.67K ≈ $-66.79K	-0.110x	+75.90%
2013-12-31	Skr598.60K ≈ $64.42K	Skr-272.15K ≈ $-29.29K	-0.455x	-328.90%
2012-12-31	Skr298.09K ≈ $32.08K	Skr59.21K ≈ $6.37K	0.199x	--

About Novakand Pharma AB (publ)

ST:LARK USA Asset Management

Market Cap

$4.79 Million

Skr44.55 Million SEK

Market Cap Rank

#28753 Global

#5921 in USA

Share Price

Skr2.25

Change (1 day)

+1.81%

52-Week Range

Skr1.84 - Skr2.56

All Time High

Skr2.56